Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by Indomitableon Jul 23, 2016 12:33pm

38 Views

Post# 25078470

RE:RCI-02 – Dermal Injector

I see it says 1 needle to 16 needles can be placed on one head. I just went over the specs after I posted this. Disregard my number of 30 I commented on at the bottom.

I wonder however if they can use more than one head, so for example if they could use 2 heads, this would mean they could inject up to 32 needles at one time? I doubt that, but was wondering anyways,